Advertisement

Journal of Hematopathology

, Volume 11, Issue 4, pp 99–105 | Cite as

Distribution of lymphomas in Mexico: a multicenter descriptive study

  • Adrian Carballo-Zarate
  • Alejandro Garcia-Horton
  • Lizbeth Palma-Berre
  • Patricia Ramos-Salazar
  • Rogelio Sanchez-Verin-Lucio
  • Jorge Valenzuela-Tamariz
  • Lourdes Molinar-Horcasitas
  • Alejandro Lazo-Langner
  • Alejandra Zarate-Osorno
Original Article

Abstract

Epidemiology of lymphoma is not well described in Mexico. We determined the frequencies and subtypes of the main non-Hodgkin’s and Hodgkin’s lymphomas in the Mexican population. Files for tissue samples for lymphomas stored in five different hospitals in Mexico City were retrieved for re-analysis and further immunostaining. The most common mature B cell, T cell/NK cell, Hodgkin’s, and precursor lymphoid neoplasms were identified according to the 2008 WHO classification of tumors. All stains were performed in the same laboratory and interpreted by three pathologists. Five thousand seven hundred seventy-two neoplasms were included. Of these, 4213 were mature B cell neoplasms (73%; 95% CI 71.83–74.12), 888 Hodgkin’s lymphomas (HLs) (15%; 95% CI 14.48–16.34), 496 mature T cell/NK neoplasms (9%; 95% CI 7.89–9.34), and 175 precursor lymphoid neoplasms (3%; 95% CI 2.62–3.5). Neoplasms had an even distribution between sexes. Main mature B cell lymphomas were diffuse large B cell lymphoma (DLBCL) (56%; 95% CI 54.39–57.39) and follicular lymphoma (FL) (20%; 95% CI 18.92–21.34). Hodgkin’s lymphomas were also classified into five main subtypes, with nodular sclerosis (47%; 95% CI 44.14–50.7) and mixed cellularity (38%; 95% CI 34.49–40.85) being the most common. The most common mature T cell/NK neoplasm was peripheral T cell lymphoma NOS/anaplastic large cell lymphoma ALK negative (44%; 95% CI 39.85–48.84). This is the first descriptive study in Mexico with a large sample of lymphomas classified according to the 2008 WHO classification. The results obtained are in keeping with the numbers described in other populations.

Keywords

Hodgkin’s lymphoma Non-Hodgkin’s lymphoma T cell 

Notes

Authorship

AC-Z, AG-H, LP-B, PR-S, RS-V-L, JV-T, and LM-H abstracted the data. AG-H and AC-Z analyzed the data. AZ-O and AL-L conceived the study. AG-H, AC-Z, and AL-L drafted the manuscript. All authors reviewed and approved the final version. All persons who contributed significantly to this work have been acknowledged.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Non-Hodgkin lymphoma - Cancer Stat Facts 2018. Available from: https://seer.cancer.gov/statfacts/html/nhl.html
  2. 2.
    Hodgkin lymphoma - Cancer Stat Facts 2018. Available from: https://seer.cancer.gov/statfacts/html/hodg.html
  3. 3.
    Meneses-García A, Ruiz-Godoy LM, Beltrán-Ortega A, Sánchez-Cervantes F, Tapia-Conyer R, Mohar A (2012) Main malignant neoplasms in Mexico and their geographic distribution, 1993-2002. Rev Investig Clin 64(4):322–329Google Scholar
  4. 4.
    Benitez-Aranda H (2002) Epidemiologia de las enfermedades hematologicas en el ambito nacional. Gac Med Mex 138(2):S12–SS8Google Scholar
  5. 5.
    Soto-Estrada G, Moreno-Altamirano L, Palma-Diaz D (2016) Panorama epidemiologico de Mexico, principales causas de morbilidad y mortalidad. Rev Fac Med UNAM 59(6):8–22Google Scholar
  6. 6.
    Cancer today 2018. Available from: http://gco.iarc.fr/today/home
  7. 7.
    Swerdlow SH, World Health Organization, International Agency for Research on Cancer (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon 585 pagesGoogle Scholar
  8. 8.
    Swerdlow SH, International Agency for Research on Cancer, World Health Organization (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon 439 pGoogle Scholar
  9. 9.
    Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjose S, Smedby KE, Chiu BCH, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadie M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, la Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS, Sampson JN (2014) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014(48):130–144CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Huh J (2012) Epidemiologic overview of malignant lymphoma. Korean J Hematol 47(2):92–104CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mendoza-Sanchez HF, Quintana-Sanchez JA, Rivera-Marquez H, Mejia-Dominguez AM, Fajardo-Gutierrez A (1998) Epidemiology of lymphomas in children residing in Mexico City. Arch Med Res 29(1):67–73PubMedGoogle Scholar
  12. 12.
    Ortega V, Verastegui E, Flores G, Meneses A, Ocadiz R, Alfaro G (1998) Non-Hodgkin’s lymphomas in Mexico. A clinicopathological and molecular analysis. Leuk Lymphoma 31(5–6):575–582CrossRefPubMedGoogle Scholar
  13. 13.
    Rendon-Macias ME, Valencia-Ramon EA, Fajardo-Gutierrez A, Rivera-Flores E (2015) Childhood lymphoma incidence patterns by ICCC-3 subtype in Mexico City metropolitan area population insured by Instituto Mexicano del Seguro Social, 1996-2010. Cancer Causes Control 26(6):849–857CrossRefPubMedGoogle Scholar
  14. 14.
    Ron-Guerrero CR-MA, Medina-Palacios CL, Lopez-Flores F (2015) Epidemiologia de los linfomas del Centro Estatal de Cancerologia de Nayarit. Rev Hematol Mex 16:109–114Google Scholar
  15. 15.
    Rivera-Luna R, Shalkow-Klincovstein J, Velasco-Hidalgo L, Cardenas-Cardos R, Zapata-Tarres M, Olaya-Vargas A et al (2014) Descriptive epidemiology in Mexican children with cancer under an open national public health insurance program. BMC Cancer 14:790CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17(8):857–872CrossRefPubMedGoogle Scholar
  17. 17.
    Ambinder AJ, Shenoy PJ, Malik N, Maggioncalda A, Nastoupil LJ, Flowers CR (2012) Exploring risk factors for follicular lymphoma. Adv Hematol 2012:626–635CrossRefGoogle Scholar
  18. 18.
    Fisher SG, Fisher RI (2004) The epidemiology of non-Hodgkin’s lymphoma. Oncogene 23(38):6524–6534CrossRefPubMedGoogle Scholar
  19. 19.
    Cerhan JR, Slager SL (2015) Familial predisposition and genetic risk factors for lymphoma. Blood 126(20):2265–2273CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Laurini JA, Perry AM, Boilesen E, Diebold J, Maclennan KA, Muller-Hermelink HK et al (2012) Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 120(24):4795–4801CrossRefPubMedGoogle Scholar
  21. 21.
    Novelli S, Briones J, Sierra J (2013) Epidemiology of lymphoid malignancies: last decade update. Springerplus 2(1):70CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Roman E, Smith AG (2011) Epidemiology of lymphomas. Histopathology 58(1):4–14CrossRefPubMedGoogle Scholar
  23. 23.
    Tirado-Gómez L, Mohar-Betancourt A (2007) Epidemiología de las Neoplasias Hemato-Oncológicas. Cancerología 2:109–120Google Scholar
  24. 24.
    Smith A, Crouch S, Howell D, Burton C, Patmore R, Roman E (2015) Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol 39(6):1103–1112CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Tadmor T, Shvidel L, Bairey O, Goldschmidt N, Ruchlemer R, Fineman R, Rahimi-Levene N, Herishanu Y, Yuklea M, Arad A, Aviv A, Polliack A, On behalf of the Israeli CLL Study Group (2014) Richter’s transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group. Am J Hematol 89(11):E218–E222CrossRefPubMedGoogle Scholar
  26. 26.
    Lossos IS, Gascoyne RD (2011) Transformation of follicular lymphoma. Best Pract Res Clin Haematol 24(2):147–163CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Warnke RA, Jones D, Hsi ED (2007) Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol 127(4):511–527CrossRefPubMedGoogle Scholar
  28. 28.
    Perry AM, Diebold J, Nathwani BN, MacLennan KA, Muller-Hermelink HK, Bast M et al (2016) Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project. Ann Hematol 95(2):245–251CrossRefPubMedGoogle Scholar
  29. 29.
    Yamaguchi K, Takatsuki K (1993) Adult T cell leukaemia-lymphoma. Baillieres Clin Haematol 6(4):899–915CrossRefPubMedGoogle Scholar
  30. 30.
    Jhuang JY, Chang ST, Weng SF, Pan ST, Chu PY, Hsieh PP, Wei CH, Chou SC, Koo CL, Chen CJ, Hsu JD, Chuang SS (2015) Extranodal natural killer/T-cell lymphoma, nasal type in Taiwan: a relatively higher frequency of T-cell lineage and poor survival for extranasal tumors. Hum Pathol 46(2):313–321CrossRefPubMedGoogle Scholar
  31. 31.
    Cabrera ME, Martinez V, Nathwani BN, Muller-Hermelink HK, Diebold J, Maclennan KA et al (2012) Non-Hodgkin lymphoma in Chile: a review of 207 consecutive adult cases by a panel of five expert hematopathologists. Leuk Lymphoma 53(7):1311–1317CrossRefPubMedGoogle Scholar
  32. 32.
    Laurent C, Do C, Gourraud PA, de Paiva GR, Valmary S, Brousset P (2015) Prevalence of common non-Hodgkin lymphomas and subtypes of Hodgkin lymphoma by nodal site of involvement: a systematic retrospective review of 938 cases. Medicine (Baltimore) 94(25):e987CrossRefGoogle Scholar
  33. 33.
    Salati M, Cesaretti M, Macchia M, Mistiri ME, Federico M (2014) Epidemiological overview of Hodgkin lymphoma across the Mediterranean Basin. Mediterr J Hematol Infect Dis 6(1):2014048CrossRefGoogle Scholar
  34. 34.
    Thomas RK, Re D, Zander T, Wolf J, Diehl V (2002) Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol 13(Suppl 4):147–152CrossRefPubMedGoogle Scholar
  35. 35.
  36. 36.
    Moreno-Estrada A, Gignoux CR, Fernandez-Lopez JC, Zakharia F, Sikora M, Contreras AV, Acuna-Alonzo V, Sandoval K, Eng C, Romero-Hidalgo S, Ortiz-Tello P, Robles V, Kenny EE, Nuno-Arana I, Barquera-Lozano R, Macin-Perez G, Granados-Arriola J, Huntsman S, Galanter JM, Via M, Ford JG, Chapela R, Rodriguez-Cintron W, Rodriguez-Santana JR, Romieu I, Sienra-Monge JJ, Navarro BR, London SJ, Ruiz-Linares A, Garcia-Herrera R, Estrada K, Hidalgo-Miranda A, Jimenez-Sanchez G, Carnevale A, Soberon X, Canizales-Quinteros S, Rangel-Villalobos H, Silva-Zolezzi I, Burchard EG, Bustamante CD (2014) Human genetics. The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science 344(6189):1280–1285CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Adrian Carballo-Zarate
    • 1
    • 2
  • Alejandro Garcia-Horton
    • 3
  • Lizbeth Palma-Berre
    • 4
  • Patricia Ramos-Salazar
    • 5
  • Rogelio Sanchez-Verin-Lucio
    • 1
    • 2
  • Jorge Valenzuela-Tamariz
    • 6
  • Lourdes Molinar-Horcasitas
    • 7
  • Alejandro Lazo-Langner
    • 3
    • 8
  • Alejandra Zarate-Osorno
    • 1
    • 2
  1. 1.Department of PathologyHospital Español de MéxicoMexico CityMexico
  2. 2.Laboratory of Pathology, Immunohistochemistry and Cytopathology, SCMexico CityMexico
  3. 3.Department of Medicine, Division of HematologyWestern UniversityLondonCanada
  4. 4.Department of OncogenomicsNational Cancer InstituteMexico CityMexico
  5. 5.Department of PathologyNational Medical Center “La Raza”Mexico CityMexico
  6. 6.Department of PathologyAngeles del Pedregal HospitalMexico CityMexico
  7. 7.Department of PathologyAngeles de Las Lomas HospitalHuixquilucanMexico
  8. 8.Department of Epidemiology and BiostatisticsWestern UniversityLondonCanada

Personalised recommendations